Share on StockTwits

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) Director Nathaniel E. David sold 1,778 shares of KYTHERA Biopharmaceuticals stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $39.20, for a total value of $69,697.60. Following the sale, the director now directly owns 492,672 shares of the company’s stock, valued at approximately $19,312,742. The sale was disclosed in a filing with the SEC, which is available at this link.

Shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) traded down 2.67% during mid-day trading on Thursday, hitting $39.03. The stock had a trading volume of 90,819 shares. KYTHERA Biopharmaceuticals has a one year low of $23.03 and a one year high of $56.36. The stock has a 50-day moving average of $35.59 and a 200-day moving average of $39.67. The company’s market cap is $884.3 million.

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($3.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $2.51. On average, analysts predict that KYTHERA Biopharmaceuticals will post $-3.33 earnings per share for the current fiscal year.

KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.